32 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2031
Next term end
22
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2033 · High confidence
Also notable
Ends Mar 2036 · High confidence
Also notable
Ends Jul 2034 · High confidence
Also notable
Ends May 2037 · High confidence
Also notable
Ends Sep 2032 · High confidence
Also notable
Ends Mar 2036 · High confidence
Also notable
Ends Mar 2039 · High confidence
Also notable
Ends Nov 2031 · High confidence
P2X4 Receptor Antagonist
US 9,382,236
Cited by 23 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Morphinan Derivative
US 10,442,802
A family of 6 related applications built on the 2019 grant. Protection runs to 2036.
P2X4 Receptor Antagonist
US 10,150,744
Granted 2018. Computed term ends 2034.
Analysis equipment for medical use
US D953,563
The most cited patent in this portfolio, cited by 31 later US patents, top 5% of design patents granted in 2022 in our data. Protection runs to 2037.
Morphinan Derivative
US 8,952,030
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2032.
USE OF MORPHINAN DERIVATIVE FOR THERAPEUTIC TREATMENT OF OPIOID delta RECEPTOR AGONIST-RELATED DISEASE
US 11,633,392
Granted 2023. Computed term ends 2036. A terminal disclaimer caps this term to an earlier patent's.
Medicament for Treating Cough
US 11,666,582
Granted 2023. Computed term ends 2039.
Preventive or Therapeutic Agent for Pain Associated with Herpes Zoster in Acute Phase
US 9,115,123
The largest patent family in this portfolio, 40 related applications, renewed at every maintenance window due so far. Protection runs to 2031.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Medicament for Treating Cough (US 11,666,582) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 1 fee due Feb 25, 2027The maintenance fee for Preventive or Therapeutic Agent for Pain Associated with Herpes Zoster in Acute Phase (US 9,115,123) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Drug for Preventing And/Or Treating Dementia (US 10,413,546) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Morphinan Derivative (US 10,442,802) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due May 12, 2027The maintenance fee for P2X4 Receptor Antagonist (US 10,472,333) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Medicament for Treatment of Multiple Sclerosis (US 11,918,589) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for P2X4 Receptor Antagonist (US 10,633,349) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 21, 2026
- 1 term has ended since Aug 21, 2026
What they patent
The largest of its 22 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,115,123 | Preventive or Therapeutic Agent for Pain Associated with Herpes Zoster in Acute Phase held by Kyushu University and Nippon Chemiphar Co., Ltd. In force · High confidence | In force | High confidence | |
| US 9,561,235 | Preventive or Therapeutic Agent for Pain Associated with Herpes Zoster in Acute Phase held by Kyushu University In force · High confidence | In force | High confidence | |
| US 8,952,030 | Morphinan Derivative In force · High confidence | In force | High confidence | |
| US 9,969,700 | P2X4 Receptor Antagonist In force · Medium confidence | In force | Medium confidence | |
| US 10,633,349 | P2X4 Receptor Antagonist In force · Medium confidence | In force | Medium confidence | |
| US 11,434,207 | P2X4 Receptor Antagonist In force · Low confidence | In force | Low confidence | |
| US 9,382,236 | P2X4 Receptor Antagonist In force · High confidence | In force | High confidence | |
| US 12,116,351 | P2X4 Receptor Antagonist In force · Medium confidence | In force | Medium confidence | |
| US 10,150,744 | P2X4 Receptor Antagonist held by Nippon Chemiphar Co., Ltd. and Kyushu University In force · High confidence | In force | High confidence | |
| US 10,472,333 | P2X4 Receptor Antagonist held by Nippon Chemiphar Co., Ltd. and Kyushu University In force · High confidence | In force | High confidence |
Also on record, not counted in the 32: 1 patent in force now held by others · 26 patents ended · 22 applications pending · 35 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.